Differential effects of recombinant human endostatin treatment on differentiated and undifferentiated blood vessels in Lewis lung cancer

Fu,Weijiang; Zhuo,Jing; Hu,Likuan

doi:10.3892/ol.2016.5446

Differential effects of recombinant human endostatin treatment on differentiated and undifferentiated blood vessels in Lewis lung cancer

Authors:
- Weijiang Fu
- Jing Zhuo
- Likuan Hu
View Affiliations

Affiliations: Department of Radiation Oncology, Cancer Center, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Ultrasonography, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: November 30, 2016 https://doi.org/10.3892/ol.2016.5446
Pages: 196-200
Copyright: © Fu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we evaluated the effects of recombinant human (rh-)endostatin treatment on differentiated and undifferentiated tumor vasculature in Lewis lung cancer for the first time. Lewis lung carcinoma models were established. The animals were treated daily with varying doses of rh‑endostatin or physiological saline for 14 days. Intravital microscopy was performed following treatment. The expression of CD31 and CD34 was determined by immunohistochemical staining, and microvessel density (MVD) was determined. Rh‑endostatin treatment significantly decreased the tumor volume compared with the control group. Rh‑endostatin treatment normalized the architecture of the vascular network. CD31+ cells decreased following rh‑endostatin treatment, whereas CD34+ cells were unaffected by the treatment. Accordingly, the MVD value of CD31+ cells in rh‑endostatin treatment groups significantly decreased (P<0.01), and the MVD value of CD34+ cells in the rh‑endostatin treatment groups did not decrease. Undifferentiated tumor blood vessels were significantly inhibited by rh‑endostatin treatment. In conclusion, the normalization of the tumor vasculature by endostatin may be related to the differential effects of endostatin on differentiated and undifferentiated blood vessels.

View Figures

View References

1	Gacche RN and Meshram RJ: Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog Biophys Mol Biol. 113:333–354. 2013. View Article : Google Scholar : PubMed/NCBI
2	Wietecha MS, Cerny WL and DiPietro LA: Mechanisms of vessel regression: toward an understanding of the resolution of angiogenesis. Curr Top Microbiol Immunol. 367:3–32. 2013.PubMed/NCBI
3	Zhang Y, Yu LK, Lu GJ, Xia N, Xie HY, Hu W, Hao KK, Xu CH and Qian Q: Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer. Asian Pac J Cancer Prev. 15:8435–8440. 2014. View Article : Google Scholar : PubMed/NCBI
4	Yao X, Qian CN, Zhang ZF, Tan MH, Kort EJ, Yang XJ, Resau JH and Teh BT: Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res. 13:161–169. 2007. View Article : Google Scholar : PubMed/NCBI
5	Qi L, Du J, Zhang Z, Diao L, Chen X and Yao X: Low differentiated microvascular density and low expression of platelet-derived growth factor-BB (PDGF-BB) predict distant metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 112:E415–E423. 2013. View Article : Google Scholar : PubMed/NCBI
6	Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G and Aprile G: Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2:1232014.PubMed/NCBI
7	Welti J, Loges S, Dimmeler S and Carmeliet P: Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 123:3190–3200. 2013. View Article : Google Scholar : PubMed/NCBI
8	Jain RK: Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 26:605–622. 2014. View Article : Google Scholar : PubMed/NCBI
9	O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
10	Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
11	Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, et al: Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 109:17561–17566. 2012. View Article : Google Scholar : PubMed/NCBI
12	Huang G and Chen L: Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol. 136:1201–1211. 2010. View Article : Google Scholar : PubMed/NCBI
13	Giatromanolaki A, Koukourakis MI, Theodossiou D, Barbatis K, O'Byrne K, Harris AL and Gatter KC: Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res. 3:2485–2492. 1997.PubMed/NCBI
14	Caraffi S, Corradi D, Campanini N, Govoni P, Rocchi L, Perris R and Mangieri D: Microcirculation density and maturity in uterine and soft tissue leiomyosarcomas: an immunohistochemical study. Histol Histopathol. 30:69–76. 2015.PubMed/NCBI
15	Suster S and Wong TY: On the discriminatory value of anti-HPCA-1 (CD-34) in the differential diagnosis of benign and malignant cutaneous vascular proliferations. Am J Dermatopathol. 16:355–363. 1994. View Article : Google Scholar : PubMed/NCBI
16	Miyata Y, Mitsunari K, Asai A, Takehara K, Mochizuki Y and Sakai H: Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy. Prostate. 75:84–91. 2015. View Article : Google Scholar : PubMed/NCBI
17	Fukumura D, Duda DG, Munn LL and Jain RK: Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 17:206–225. 2010. View Article : Google Scholar : PubMed/NCBI
18	Poblet E, Gonzalez-Palacios F and Jimenez FJ: Different immunoreactivity of endothelial markers in well and poorly differentiated areas of angiosarcomas. Virchows Arch. 428:217–221. 1996.PubMed/NCBI
19	Barczyk M, Carracedo S and Gullberg D: Integrins. Cell. 339:269–280. 2010.
20	Dong XP, Xiao TH, Dong H, Jiang N and Zhao XG: Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice. Asian Pac J Cancer Prev. 14:3079–3083. 2013. View Article : Google Scholar : PubMed/NCBI
21	Xiao L, Yang S, Hao J, Yuan X, Luo W, Jiang L, Hu Y, Fu Z, Zhang Y and Zou C: Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis. Cancer Lett. 359:148–154. 2015. View Article : Google Scholar : PubMed/NCBI
22	Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y, Chen J, Hu X, Zhou Q, Wang Y, et al: Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One. 7:e346462012. View Article : Google Scholar : PubMed/NCBI
23	Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ and Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64:3731–3736. 2004. View Article : Google Scholar : PubMed/NCBI
24	von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, Herms J and Winkler F: Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res. 17:6192–6205. 2011. View Article : Google Scholar : PubMed/NCBI